EVENTS | VIEW CALENDAR
Agilent and Transcriptic team up
SANTA CLARA, Calif.—Agilent Technologies Inc. and Transcriptic Inc. have agreed to partner their technologies to provide a solution for convenient, broad-scale synthetic and discovery biology research.
“We’re excited to combine our genome engineering tools with automated experimentation,” said Herman Verrelst, Agilent vice president and general manager of the company’s Genomics Solutions Division and Clinical Applications Division. “Transcriptic’s services are validated, scalable, and accessible from anywhere in the world, which will enhance the market for our industry-leading reagents.”
“Agilent’s genomics market leading products, and Transcriptic’s goal of developing industry leading protocols and reagents accessible to their users, presented a clear space where collaboration would be of interest and benefit to both companies,” says Dr. Charmian Cher, director of global launch excellence and genomics at Agilent Technologies. “Transcriptic approached Agilent with the goal of validating and implementing Agilent workflows on the Transcriptic platform. Agilent is committed to helping foster innovation by working with small, novel companies such as Transcriptic, and saw this as a unique potential for growth.”
Agilent continues its strong program of fostering innovation using the Agilent portfolio by collaborating with rising companies such as Transcriptic to develop novel synthetic biology solutions. Transcriptic’s automated discovery biology platform enables scalable life-sciences research through a convenient and simple web interface. Biologists who use the platform can control their science and generate data remotely via the cloud.
“Since their beginning, Transcriptic has been a customer of Agilent life-sciences and genomics products, including the Bravo Automated Liquid Handling Platform for all of their robotic modules, as well as many of Agilent’s synthetic biology reagents and kits. However, this is the first collaboration between the two companies that offers customers a convenient and validated workflow for Agilent’s synthetic biology solutions on the Transcriptic platform,” Cher says.
Transcriptic will add multiple Agilent Genomics product lines for mutagenesis and cloning to the protocol library within the Transcriptic robotic cloud laboratory. The first in the series—QuikChange Lightning—will accelerate the generation of multiple mutants for large protein function projects. Providing cutting-edge Agilent bioreagents in a robotic laboratory setting will allow a global customer base to automate and optimize workflows for rapid and efficient research discoveries.
“Through this partnership, Agilent will continue its strong program of fostering innovation using the Agilent portfolio, by collaborating with companies such as Transcriptic to develop novel synthetic biology solutions. Biologists who use the platform can now control their science and generate data remotely via the cloud,” Cher says.
Cher continues, “Transcriptic’s automated discovery biology platform enables scalable life-science research through a convenient and simple web interface. Transcriptic will add multiple Agilent genomics product lines for mutagenesis and cloning to the protocol library within the Transcriptic robotic cloud laboratory. These additional protocols will enable Transcriptic to grow their customer base within the large user base for these industry leading products.”
“Agilent QuikChange site-directed mutagenesis kits have an unsurpassed reputation for being reliable and easy to use,” said Yvonne Linney, chief operating officer at Transcriptic. “By bringing these products to Transcriptic, we will make it extremely easy for customers to scale up their research, using many mutants to produce very large datasets for exploring protein function.”
The companies recently presented the combined solution at the iGEM 2016 Giant Jamboree to teams of budding synthetic biologists from around the world. For more information, visit https://learn.transcriptic.com/quikchange-lightning.